Finzati - Logo
HCM logo

HUTCHMED (China) Limited

HCM • Drug Manufacturers - Specialty & Generic
$0.00
— 0.00 (0.00%)
EarningsLatest report: Dec 31, 2025
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$1.88B
Growth
15.0%
Cash Flow
1/5
Trend
Volatile
Evidence
Stable or improving margins · 83.3%Positive revenue growth · 9.3%Reasonable earnings multiple · 4.99Manageable debt level · 0.08Healthy liquidity · 4.96
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Mar 5, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$1.88B
52W Range9.77 - 18.30
Beta0.43
Gross Margin38.68%
Oper. Margin-9.95%
Profit Margin83.30%
Debt/Eq0.08
Current Ratio4.96
Quick Ratio4.83
Revenue 5Y14.98%

Investment DNA

How strong this company looks for long-term investors

69
out of 100
Business Quality
Margins, moat, returns
65/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
91/100
Price Attractiveness
Cheap or expensive today
84/100
Why this score▼
Stable or improving margins · 83.3%Positive revenue growth · 9.3%Reasonable earnings multiple · 4.99Manageable debt level · 0.08Healthy liquidity · 4.96

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-07-31
Low
$13.60
Mean
$13.80
Median
$13.80
High
$14.00

Company Overview

IPO: 3/16/2016
Industry: Drug Manufacturers - Specialty & Generic
P/B i: 1.85
Debt / Equity i: 0.08
Operating Margin: -9.95%
Net Margin: 83.30%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.08
Current Ratio: 4.96
Quick Ratio: 4.83
Status: Good

Insider Transactions

Recent executive and insider activity

Chiu Lorenso
Transaction: 05/20/2026
BUY
Change
+5,176
Price
Not reported
Filing
05/21/2026
Type
BUY
Chiu Lorenso
Transaction: 05/20/2026
BUY
Change
+8,863
Price
Not reported
Filing
05/21/2026
Type
BUY
Su Wei-guo
Transaction: 05/20/2026
BUY
Change
+75,140
Price
Not reported
Filing
05/21/2026
Type
BUY